UY30521A1 - Pirazolo[1,5-a] pirimidinas, procesos, usos y composiciones - Google Patents

Pirazolo[1,5-a] pirimidinas, procesos, usos y composiciones

Info

Publication number
UY30521A1
UY30521A1 UY30521A UY30521A UY30521A1 UY 30521 A1 UY30521 A1 UY 30521A1 UY 30521 A UY30521 A UY 30521A UY 30521 A UY30521 A UY 30521A UY 30521 A1 UY30521 A1 UY 30521A1
Authority
UY
Uruguay
Prior art keywords
pirazolo
pyrimidins
compositions
processes
sleep
Prior art date
Application number
UY30521A
Other languages
English (en)
Inventor
Antonio Guglietta
Palomer Albert
Anglada Luis
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of UY30521A1 publication Critical patent/UY30521A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a nuevas pirazolo[1,5-a]pirimidinas, las cuales son utiles para tratar o prevenir la ansiedad, epilepsia y los trastornos del sueno incluyendo el insomnio, y para inducir sedacion-hipnosis, anestesia, sueno y relajacion muscular.
UY30521A 2006-08-04 2007-08-02 Pirazolo[1,5-a] pirimidinas, procesos, usos y composiciones UY30521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06118454A EP1884516A1 (en) 2006-08-04 2006-08-04 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions

Publications (1)

Publication Number Publication Date
UY30521A1 true UY30521A1 (es) 2008-02-29

Family

ID=37864479

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30521A UY30521A1 (es) 2006-08-04 2007-08-02 Pirazolo[1,5-a] pirimidinas, procesos, usos y composiciones

Country Status (25)

Country Link
US (1) US8158632B2 (es)
EP (2) EP1884516A1 (es)
JP (1) JP2009545568A (es)
KR (1) KR20090046916A (es)
CN (1) CN101641359A (es)
AR (1) AR062205A1 (es)
AT (1) ATE469906T1 (es)
AU (1) AU2007280412A1 (es)
BR (1) BRPI0715169A2 (es)
CA (1) CA2659969A1 (es)
CL (1) CL2007002262A1 (es)
CY (1) CY1110757T1 (es)
DE (1) DE602007006966D1 (es)
DK (1) DK2059521T3 (es)
ES (1) ES2346810T3 (es)
HK (1) HK1129105A1 (es)
MX (1) MX2009001149A (es)
NO (1) NO20090972L (es)
PL (1) PL2059521T3 (es)
PT (1) PT2059521E (es)
RU (1) RU2458063C2 (es)
SI (1) SI2059521T1 (es)
TW (1) TW200815445A (es)
UY (1) UY30521A1 (es)
WO (1) WO2008015253A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
WO2010053127A1 (ja) * 2008-11-05 2010-05-14 協和発酵キリン株式会社 α1GABAA受容体またはα5GABAA受容体の調整剤
ES2540867T3 (es) * 2010-02-26 2015-07-14 Mitsubishi Tanabe Pharma Corporation Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10
CN102807569B (zh) * 2012-08-21 2015-02-25 四川大学 一种镇静催眠的化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4847256A (en) * 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
EP0521622B1 (en) * 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
US6399621B1 (en) * 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
ES2222813B1 (es) * 2003-07-24 2005-12-16 Ferrer Internacional, S.A. N-(3-(3-sustituidas-pirazolo(1,5-a)pirimidin-7-il)-fenil)-sulfonamidas y composiciones y metodos relacionados.
TWI252851B (en) * 2003-07-24 2006-04-11 Ferrer Int 7-substituted 3-nitro-pyrazolo[1,5-a]pyrimidines and compositions and methods related thereto
EP1736475A1 (en) 2005-06-21 2006-12-27 Ferrer Internacional, S.A. Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
DE102005028765B4 (de) * 2005-06-22 2016-01-21 Airbus Operations Gmbh Verfahren zur Herstellung eines Verstärkungsprofils
EP1956021A1 (en) * 2006-10-11 2008-08-13 Ferrer Internacional, S.A. Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound

Also Published As

Publication number Publication date
US8158632B2 (en) 2012-04-17
RU2458063C2 (ru) 2012-08-10
KR20090046916A (ko) 2009-05-11
PT2059521E (pt) 2010-08-26
JP2009545568A (ja) 2009-12-24
HK1129105A1 (en) 2009-11-20
NO20090972L (no) 2009-04-30
EP2059521B1 (en) 2010-06-02
CA2659969A1 (en) 2008-02-07
PL2059521T3 (pl) 2010-11-30
CL2007002262A1 (es) 2008-01-18
AR062205A1 (es) 2008-10-22
WO2008015253A1 (en) 2008-02-07
TW200815445A (en) 2008-04-01
CY1110757T1 (el) 2015-06-10
DE602007006966D1 (de) 2010-07-15
US20090264448A1 (en) 2009-10-22
CN101641359A (zh) 2010-02-03
MX2009001149A (es) 2009-03-02
DK2059521T3 (da) 2010-09-27
AU2007280412A1 (en) 2008-02-07
EP2059521A1 (en) 2009-05-20
SI2059521T1 (sl) 2010-09-30
RU2009107734A (ru) 2010-09-10
ATE469906T1 (de) 2010-06-15
EP1884516A1 (en) 2008-02-06
ES2346810T3 (es) 2010-10-20
BRPI0715169A2 (pt) 2013-06-11

Similar Documents

Publication Publication Date Title
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CY1120054T1 (el) Ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νευρολογικων και ψυχολογικων διαταραχων
UY29618A1 (es) " pirazolo(1,5-a) pirimidinas halogenadas, métodos, usos, composiciones e intermedios"
UY28376A1 (es) Agentes terapéuticos
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
CR8718A (es) Compuesto de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
UY28752A1 (es) Agentes terapeuticos
MX345535B (es) Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
CL2008003120A1 (es) Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras.
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
EA200900782A1 (ru) Композиции и способы, предназначенные для лечения мышечных и сердечно-сосудистых нарушений
UY26924A1 (es) Derivados de fenoxibencilamina como ssri
UY29790A1 (es) Sales de diariloimidazola-4-carboxamidas, composiciones que las contienen, procesos de preparación y aplicaciones
CL2011001845A1 (es) Uso de un agente terapeutico en el talamo mediante distribucion por conveccion mejorada (ced) para tratar un trastorno neurologico cortical.
ECSP066964A (es) Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos
UY30521A1 (es) Pirazolo[1,5-a] pirimidinas, procesos, usos y composiciones
UY29741A1 (es) Sales de 1,5- diaril pirazol-3-carboxamidas, procesos de preparación, composeciones farmacéuticas que las contienen, aplicaciones y métodos de uso.
UY30529A1 (es) Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones
CL2009000322A1 (es) Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros.
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos